REPLIGEN CORP Stock Issued During Period, Value, Conversion of Units
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- REPLIGEN CORP stock issued during period, value, conversion of units for the quarter ending 2024-12-31 was $0.00.
- REPLIGEN CORP stock issued during period, value, conversion of units for the quarter ending 2024-09-30 was -$7.00K.
- REPLIGEN CORP stock issued during period, value, conversion of units for the quarter ending 2024-06-30 was -$53.00K.
- REPLIGEN CORP stock issued during period, value, conversion of units for the quarter ending 2024-03-31 was -$55.00K.
- REPLIGEN CORP stock issued during period, value, conversion of units for fiscal 2024 was -$114.00K.
- REPLIGEN CORP stock issued during period, value, conversion of units for fiscal 2023 was -$13.00K.
- REPLIGEN CORP stock issued during period, value, conversion of units for fiscal 2022 was -$6.00K, a 400.00% decline from fiscal 2021.
- REPLIGEN CORP stock issued during period, value, conversion of units for fiscal 2021 was $2.00K.
| Period end | Stock Issued During Period, Value, Conversion of Units 3 month | Stock Issued During Period, Value, Conversion of Units 12 month |
|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$114.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | -$7.00K 10-Q · filed 2025-11-04 | -$115.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$53.00K 10-Q · filed 2025-08-07 | -$118.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$55.00K 10-Q · filed 2025-04-29 | -$68.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-26 | -$13.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | -$10.00K 10-Q/A · filed 2024-11-18 | |
| 2023-06-30 | -$3.00K 10-Q/A · filed 2024-11-18 | |
| 2022-12-31 | -$1.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14 | -$6.00K 10-K · filed 2025-03-14 |
| 2022-09-30 | $0.00 10-Q/A · filed 2024-11-18 | -$5.00K derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-06-30 | -$3.00K 10-Q/A · filed 2024-11-18 | -$4.00K derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-03-31 | -$2.00K 10-Q/A · filed 2024-11-18 | -$1.00K derived: sum of 4 quarters · filed 2024-11-18 |
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | $2.00K 10-K/A · filed 2024-11-18 |
| 2021-09-30 | $1.00K 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | |
| 2021-03-31 | $1.00K 10-Q · filed 2022-04-27 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $198.76M 10-K · filed 2022-02-17 |
| 2019-09-30 | $198.75M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $2.00K 10-Q · filed 2020-07-30 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $0.00 10-K · filed 2021-02-24 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |